📊 IMNN Key Takeaways
Is Imunon, Inc. (IMNN) a Good Investment?
Imunon exhibits critical financial distress with only $500K in annual revenue while burning $4.3M in free cash flow, providing less than 12 months of operational runway at current burn rates. The company carries $6.1M in long-term debt against $4.8M cash and negative interest coverage of -21.9x, creating acute solvency risk. Without significant revenue acceleration or capital restructuring, insolvency is a material threat within the next 12-18 months.
Imunon shows minimal revenue and extremely negative profitability, indicating a pre-commercial profile dependent on external funding. While liquidity is currently adequate, cash covers less than a year of burn and interest coverage is deeply negative, raising refinancing and dilution risks. Without a clear path to revenue inflection or substantial non-dilutive funding, sustained losses are likely.
Imunon, Inc. Key Strengths (IMNN)
- Maintains positive cash balance of $4.8M providing near-term liquidity buffer
- Current ratio of 1.59x indicates acceptable short-term liquidity on surface
- Improvement in EPS from -$2.08 to -$0.84 YoY shows relative operational improvement
- Solid near-term liquidity (current ratio 2.32x)
- Cash-heavy asset base with low capex needs
- Improving net loss/EPS trend YoY
IMNN Stock Risks: Imunon, Inc. Investment Risks
- Operating cash flow of -$4.0M annually with only $4.8M cash creates ~12-month solvency window
- Debt-to-equity ratio of 1.81x with negative interest coverage (-21.9x) indicates inability to service debt from operations
- Revenue of $500K with 0% growth and operating losses of $4.3M suggest pre-commercial or failed product pipeline
- Long-term debt of $6.1M exceeds total equity of $3.4M, creating refinancing risk
- No insider purchases in 90 days despite financial distress suggests lack of management confidence
- Pharmaceutical company with minimal revenue indicates failed or delayed product commercialization
- De minimis, flat revenue base drives funding dependence
- High cash burn and deeply negative margins shorten runway
- Leverage with negative interest coverage heightens refinancing/dilution risk
Key Metrics to Watch
- Quarterly cash burn rate and months of cash remaining
- Revenue growth trajectory and evidence of product commercialization
- Debt refinancing schedule and covenant compliance status
- Insider buying activity indicating management confidence
- Operating cash flow path to positive territory
- Operating cash flow (TTM burn)
- Cash & equivalents and runway months
Imunon, Inc. (IMNN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Imunon, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
IMNN Profit Margin, ROE & Profitability Analysis
IMNN vs Healthcare Sector: How Imunon, Inc. Compares
How Imunon, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Imunon, Inc. Stock Overvalued? IMNN Valuation Analysis 2026
Based on fundamental analysis, Imunon, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Imunon, Inc. Balance Sheet: IMNN Debt, Cash & Liquidity
IMNN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Imunon, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-16.94 indicates the company is currently unprofitable.
IMNN Revenue Growth, EPS Growth & YoY Performance
IMNN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $125.0K | -$3.5M | $-0.37 |
| Q2 2023 | $125.0K | -$5.5M | $-0.61 |
| Q1 2023 | $125.0K | -$5.5M | $-0.68 |
| Q3 2022 | $125.0K | -$5.4M | $-0.87 |
| Q2 2022 | $125.0K | -$5.4M | $-0.87 |
| Q1 2022 | $125.0K | -$5.7M | $-1.82 |
| Q3 2021 | $125.0K | -$5.4M | N/A |
| Q2 2021 | $125.0K | -$5.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Imunon, Inc. Dividends, Buybacks & Capital Allocation
IMNN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Imunon, Inc. (CIK: 0000749647)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMNN
What is the AI rating for IMNN?
Imunon, Inc. (IMNN) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMNN's key strengths?
Claude: Maintains positive cash balance of $4.8M providing near-term liquidity buffer. Current ratio of 1.59x indicates acceptable short-term liquidity on surface. ChatGPT: Solid near-term liquidity (current ratio 2.32x). Cash-heavy asset base with low capex needs.
What are the risks of investing in IMNN?
Claude: Operating cash flow of -$4.0M annually with only $4.8M cash creates ~12-month solvency window. Debt-to-equity ratio of 1.81x with negative interest coverage (-21.9x) indicates inability to service debt from operations. ChatGPT: De minimis, flat revenue base drives funding dependence. High cash burn and deeply negative margins shorten runway.
What is IMNN's revenue and growth?
Imunon, Inc. reported revenue of $500.0K.
Does IMNN pay dividends?
Imunon, Inc. does not currently pay dividends.
Where can I find IMNN SEC filings?
Official SEC filings for Imunon, Inc. (CIK: 0000749647) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMNN's EPS?
Imunon, Inc. has a diluted EPS of $-0.84.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IMNN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Imunon, Inc. has a D grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IMNN stock overvalued or undervalued?
Valuation metrics for IMNN: ROE of -126.5% (sector avg: 15%), net margin of -849.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IMNN's AI grade for 2026?
Our dual AI analysis gives Imunon, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMNN's free cash flow?
Imunon, Inc.'s operating cash flow is $-4.0M, with capital expenditures of $280.6K. FCF margin is -853.1%.
How does IMNN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -849.8% (avg: 12%), ROE -126.5% (avg: 15%), current ratio 1.59 (avg: 2).
Is Imunon, Inc. carrying too much debt?
IMNN has a debt-to-equity ratio of 1.81x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.59 suggests adequate short-term liquidity.